National Agency for Food and Drug Administration and Control

As Muslims across Nigeria and around the world celebrate Eid al-Adha, NAFDAC extends warm greetings and best wishes to all faithful.

Eid al-Adha is a season of sacrifice, compassion, obedience, and gratitude, values that strengthen our unity as a people and inspire us to work together for a healthier, safer, and more prosperous nation.

As families and communities gather to celebrate, NAFDAC encourages Nigerians to remain vigilant and make safety a priority by purchasing food, drinks, medicines, cosmetics, and other regulated products only from trusted and authorised sources.

May this blessed season bring peace, joy, good health, and renewed hope to every home.
Eid Mubarak! 🌙

ℹ️ NAFDAC has been recognised as one of Nigeria’s top-performing public institutions in the latest Fiscal Responsibility and Institutional Performance Report released by Transparency Watch Initiative.

According to the report, the Agency was commended for its regulatory enforcement, public health protection efforts, and intensified campaign against counterfeit and substandard products.

This recognition highlights the impact of NAFDAC’s ongoing reforms, strengthened regulatory oversight, and its commitment to safeguarding the health and well-being of Nigerians.

Read the full report by PUNCH Newspaper ⬇️

NRS, NAFDAC, others ranked top performing Nigerian public institutions A new report by Transparency Watch Initiative ranks the top-performing Nigerian public institutions, highlighting FIRS, NAFDAC, and others for excellence.

NAFDAC Destroys Counterfeit, Expired and Unwholesome Products Worth Over ₦1.8 Billion in Abuja

NAFDAC has destroyed counterfeit, substandard, falsified, expired and unwholesome regulated products valued at over ₦1.8 billion at the Kuje dumpsite in the Federal Capital Territory (FCT).

The destruction exercise involved the incineration of counterfeit medicines, banned sachet alcohol, expired pharmaceuticals, fake chemicals and other unsafe products seized across Abuja and surrounding areas, including items voluntarily submitted by companies, NGOs, and the Association of Community Pharmacists of Nigeria (ACPN).

Speaking during the exercise, the Director-General of NAFDAC, Prof. Mojisola Adeyeye, represented by the Director of Investigation & Enforcement, Dr. Martins Iluyomade, warned that counterfeit drug syndicates now deploy sophisticated cloning techniques to imitate genuine products, making it increasingly difficult for consumers to identify fake items.

He disclosed that the Agency recently intercepted several containers of suspicious products falsely declared to evade detection at the ports, stressing the need for stronger inter-agency collaboration and public vigilance.

NAFDAC reiterates that the destruction exercise demonstrates the Agency’s commitment to ensuring that seized products do not re-enter circulation. The Agency also reaffirms its commitment to enforcing the ban on alcoholic beverages packaged in sachets and PET bottles below 200ml, warning that enforcement actions and prosecution will extend to traders found in possession of such products.

NAFDAC urges Nigerians to avoid patronising suspiciously cheap medicines and other regulated products, and to report suspicious activities to the nearest NAFDAC office or the NAFDAC Call Centre.

ℹ️ NAFDAC has concluded investigations into public concerns regarding the extended shelf life of BON Bread and confirms that the manufacturer is in compliance with regulatory standards.

Laboratory analysis showed that approved preservatives were used within internationally accepted limits, while no objectionable substances, including bromate, were detected in the bread samples tested.

Read the full press release ⬇️ for details on the investigation and findings.

Public Alert No. 024/2026.
Alert on counterfeit Augmentin 625mg Tablets (Batch No. AC3N) in Nigeria


https://bit.ly/42Uakzq

NAFDAC is notifying healthcare providers and the public of the circulation of counterfeit or falsified Augmentin 625mg Tablets (2 x 7 tablets pack) with Batch No. AC3N in Nigeria. NAFDAC has received information from the Marketing Authorisation Holder for GlaxoSmithKline products in Nigeria regarding suspected counterfeit Augmentin 625mg Tablets.

This alert follows a series of complaints received by the genuine manufacturer, GlaxoSmithKline (GSK), regarding suspected counterfeit Augmentin 625mg Tablets bearing the Batch No. AC3N, circulating in Nigeria.

GSK evaluated and confirmed that the suspected product was counterfeit after reviewing documentary evidence, photographs, and a video from social media. Although the product shared the same batch number as authentic stock previously supplied to Nigeria, it exhibited inconsistent manufacturing and expiry dates, indicating that it had been falsified.

Findings from the manufacturer’s investigation:
• Batch AC3N was manufactured at Worthing, United Kingdom, on 23 August 2023.
• The batch was packed between 19 and 20 September 2023.
• No batch with the number AC3N was produced in September 2025.
• The manufacturing and expiry dates shown on the suspect sample (Manufactured: September 2025 / Expiry: September 2028) are inconsistent with GSK production records and cannot be attributed to a GSK-produced batch.
• Packaging-level discrepancies, including textual errors and poor fin seal quality, were identified.
• Based on the evidence reviewed, the product was assessed as counterfeit.

Augmentin (amoxicillin/clavulanic acid) is an antibiotic used for the treatment of bacterial infections. Any falsified version may contain incorrect amounts of active ingredients, no active ingredient, or harmful substances.

Product Details:
• Product Name: Augmentin 625mg Tablets
• Pack Size: 2 x 7 Tablets
• Batch Number: AC3N
• Manufacturer of Genuine Product: GlaxoSmithKline (GSK), Worthing Site, United Kingdom

Healthcare professionals are advised to review stock in hospitals, clinics, and pharmacy stores, immediately quarantine any suspected counterfeit stock, and discontinue the sale or distribution of any suspected counterfeit.

Report any suspected falsified or compromised products (medicines or medical devices) to the nearest NAFDAC office, call 0800-162-3322, or send an email to [email protected]

NAFDAC, KMDMC Strengthen Partnership to Enhance Public Health Protection in Kaduna

NAFDAC has strengthened collaboration with the Kaduna Markets Development and Management Company (KMDMC) to promote regulatory compliance and protect public health in Kaduna State. This followed a courtesy visit by the Director, North-West Zone, Mr. Dadi Nantim Mullah, and his team to the management of KMDMC.

Both organisations agreed to establish a joint standing committee to facilitate continuous coordination, address industry challenges, and strengthen compliance within markets across the state. Discussions also focused on trader sensitisation, consumer safety, and improving adherence to regulatory standards for regulated products.

NAFDAC reaffirmed its commitment to working with stakeholders to ensure that products distributed in Nigerian markets are safe, authentic, and compliant with national health regulations.

NAFDAC, FCCPC Sign MoU to Strengthen Consumer Protection and Public Health Regulation

NAFDAC has signed a Memorandum of Understanding (MoU) with the Federal Competition and Consumer Protection Commission (FCCPC) to strengthen collaboration in safeguarding public health, protecting consumers, and reducing regulatory overlaps between both agencies.

Speaking at the signing ceremony, the Director-General of NAFDAC, Prof. Mojisola Adeyeye, described the agreement as a strategic framework for enhanced synergy, cooperation, and information sharing in the discharge of both agencies’ mandates. She emphasised the importance of strong implementation of the MoU, particularly in the areas of investigation, consumer protection, and regulatory coordination.

The Executive Vice Chairman of FCCPC, Mr. Tunji Bello, commended NAFDAC’s leadership and noted that the agreement represents a deliberate step towards more coordinated regulation within Nigeria’s consumer market. The MoU, which runs for four years and can be renewed, is expected to establish effective mechanisms for sustained inter-agency collaboration to protect the public interest.

NAFDAC Convenes Stakeholders’ Engagement to Showcase Regulatory Transformation and Strengthen Nigeria’s Commitment to the African Medicines Agency

NAFDAC, in collaboration with World Bank, the Bank of Industry, and the Federal Ministry of Health and Social Welfare, convened a One-Day Stakeholders’ Engagement on Monday, 5 May 2026, at the Abuja Intercontinental Hotel. The event, themed “Nigeria’s Leadership in Strengthening Medicines Regulation and Public Health in Africa,” brought together key national, regional, and international stakeholders to advance dialogue on regulatory excellence and continental collaboration.

The Director-General of NAFDAC, Prof. Mojisola Adeyeye, highlighted NAFDAC’s regulatory transformation in recent years, driven by strategic reforms, digital innovation, strengthened enforcement, and alignment with international best practices. These efforts have enhanced transparency, efficiency, and turnaround time for regulatory processes, while reinforcing the Agency’s capacity to safeguard public health and support national development. Nigeria’s growing regulatory maturity continues to position the country as a leading authority in medicines regulation across Africa.

A central focus of the engagement was Nigeria’s commitment to the African Medicines Agency (AMA), an African Union initiative aimed at harmonising medicines regulation, improving access to quality-assured medical products, and strengthening health systems across the continent. Stakeholders emphasised the importance of regional cooperation in pharmacovigilance, manufacturing oversight, and the fight against substandard and falsified medical products.

The forum also provided a platform to deepen partnerships with development agencies, the private sector, academia, and international organisations, while exploring investment opportunities in local pharmaceutical manufacturing and regulatory capacity development. Participants reaffirmed the need for sustained collaboration to drive innovation, strengthen systems, and enhance access to safe, effective, and quality medicines.

NAFDAC reiterated its commitment to advancing regulatory excellence, promoting public health, and supporting Nigeria’s leadership role in Africa’s health security agenda. The Agency emphasised that the outcomes of the engagement will contribute to strengthening stakeholder confidence, fostering investment, and accelerating the implementation of a robust, modern regulatory framework aligned with continental and global standards.